文献速递中医儿科中药与中成药合理使用

化湿败毒颗粒治疗儿童轻型COVID-19的随机对照试验

Huashi baidu granule in the treatment of pediatric patients with mild coronavirus disease 2019: A single-center, open-label, parallel-group randomized controlled clinical trial.
PubMed 文献 · Front Pharmacol · 2023-01-19

本研究为单中心、开放标签、平行组随机对照试验,纳入108例3-18岁实验室确诊轻型COVID-19患儿,按2:1随机分配接受化湿败毒颗粒或复方福尔可定口服溶液治疗5天。结果显示干预组SARS-CoV-2核酸转阴时间中位数显著短于对照组(3天 vs 5天,p=0.047),第3天症状总评分中位数显著更低(1 vs 2,p=0.036),两组抗生素使用频率和副作用无显著差异。

要点

  • 化湿败毒颗粒可缩短儿童轻型COVID-19核酸转阴时间。
  • 化湿败毒颗粒可降低第3天症状总评分。
  • 两组抗生素使用及副作用无显著差异。

核心结论

  • 化湿败毒颗粒是安全有效的口服中药复方颗粒,在儿童奥密克戎感染中表现良好。

研究设计与样本

  • 单中心、开放标签、平行组随机对照试验,纳入108例3-18岁实验室确诊轻型COVID-19患儿,按2:1随机分配。

主要发现

  • 干预组SARS-CoV-2核酸转阴时间中位数(IQR)为3(3-5)天,对照组为5(3-6)天,p=0.047。
  • 干预组第3天症状总评分中位数(IQR)为1(0-2),对照组为2(0-3),p=0.036。
  • 两组抗生素使用频率和副作用频率无显著差异。

关键数值与推荐

  • 干预组口服化湿败毒颗粒连续5天,对照组口服复方福尔可定口服溶液连续5天。
  • 主要结局为SARS-CoV-2核酸转阴时间和症状评分。

临床怎么用

  • 对于儿童轻型COVID-19,可考虑使用化湿败毒颗粒以缩短核酸转阴时间和改善症状。

局限性

  • 单中心、开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Since late February 2022, a wave of coronavirus disease 2019 (COVID-19) mainly caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant rapidly appeared in Shanghai, China. Traditional Chinese medicine treatment is recommended for pediatric patients; however, the safety and efficacy remain to be confirmed. We conducted a single-center, open-label, parallel-group randomized controlled trial to assess the efficacy and safety of a Chinese herb compound, Huashi Baidu granule (HSBDG) in pediatric patients with laboratory-confirmed mild COVID-19. Methods: 108 recruited children (aged 3-18 years) with laboratory-confirmed mild COVID-19 were randomly allocated 2:1 to receive oral HSBDG for five consecutive days (intervention group) and to receive compound pholcodine oral solution for five consecutive days (control group). The negative conversion time of SARS-CoV-2 nucleic acid and symptom scores were recorded. Results: The median negative conversion time of SARS-CoV-2 nucleic acid was significantly shorter in the intervention group than in the control group (median days [interquartile range (IQR)]: 3 [3-5] vs. 5 [3-6]; p = 0.047). The median total symptom score on day 3 was significantly lower in the intervention group than in the control group (median total symptom score [IQR]: 1 [0-2] vs. 2 [0-3]; p = 0.036). There was no significant differences in the frequency of antibiotic use and side effects between the two groups. Conclusion: HSBDG is a safe, effective oral Chinese herbal compound granule, which shows a good performance within the Omicron wave among pediatric patients.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Chen J, Tang Q, Zhang B, et al. Huashi baidu granule in the treatment of pediatric patients with mild coronavirus disease 2019: A single-center, open-label, parallel-group randomized controlled clinical trial. Front Pharmacol. 2023. PMID: 36744267. doi:10.3389/fphar.2023.1092748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。